Market Access News | pharmaphorum

News

Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.

News

FDA has approved the 2026 COVID vaccine formulations, but last year's narrower recommendation stands, leaving open questions about access.

News

The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.

News

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and non-traditional PBMs to cut costs.

News

The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).

News

Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.